Opthea (OPT.AX)

Executive Summary

Opthea, an Australian clinical-stage biotech, has strategically pivoted from retinal diseases to focus on lymphangioleiomyomatosis (LAM), a rare lung disorder with high unmet need, leveraging its proprietary sozinibercept (OPT-302) platform. The company suffered a setback in 2025 with the termination of two Phase 3 trials in neovascular age-related macular degeneration due to insufficient efficacy, but its cash runway and novel approach targeting VEGF-C/D inhibition offer renewed promise in LAM, where pathological lymphatic and vascular dysfunction drive disease progression. With no approved therapies for LAM, Opthea's repositioning addresses a significant market opportunity, though clinical validation remains pending.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1/2 trial in LAM70% success
• Q2 2026Regulatory guidance from FDA for LAM program80% success